Dysferlin-deficient muscular dystrophy and innate immune activation

FEBS Journal

Volumn 280, Issue 17, 2013, Pages 4165-4176

  Mariano, Andrew ^a   Henning, Audrey ^a   Han, Renzhi ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

dysferlin; inflammation; innate immune system; membrane repair; muscular dystrophy

Indexed keywords

CRYOPYRIN; DYSFERLIN; GLUCOCORTICOID; IMMUNOGLOBULIN; LIPOCORTIN 2; LIPOCORTIN 5; PHOSPHATIDYLSERINE; RITUXIMAB; TOLL LIKE RECEPTOR;

DYSFERLIN DEFICIENT MUSCULAR DYSTROPHY; DYSFERLINOPATHY; HUMAN; INFLAMMATION; INNATE IMMUNITY; MEDIATOR RELEASE; MUSCLE CELL MEMBRANE REPAIR; MUSCLE FIBER MEMBRANE; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW;

DYSFERLIN; INFLAMMATION; INNATE IMMUNE SYSTEM; MEMBRANE REPAIR; MUSCULAR DYSTROPHY;

ANIMALS; CELL MEMBRANE; IMMUNITY, INNATE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES;

EID: 84882662230     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12261     Document Type: Review

References (109)

1. McNeil PL, Miyake K, &, Vogel SS, (2003) The endomembrane requirement for cell surface repair. Proc Natl Acad Sci USA 100, 4592-4597.
2. Bi GQ, Alderton JM, &, Steinhardt RA, (1995) Calcium-regulated exocytosis is required for cell membrane resealing. J Cell Biol 131, 1747-1758.
3. Miyake K, &, McNeil PL, (1995) Vesicle accumulation and exocytosis at sites of plasma membrane disruption. J Cell Biol 131, 1737-1745.
4. Togo T, &, Steinhardt RA, (2004) Nonmuscle myosin IIA and IIB have distinct functions in the exocytosis-dependent process of cell membrane repair. Mol Biol Cell 15, 688-695.
5. 2+-regulated exocytosis. J Cell Biol 138, 999-1008.
6. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, &, Campbell KP, (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423, 168-172.
7. Lennon NJ, Kho A, Bacskai BJ, Perlmutter SL, Hyman BT, &, Brown RH Jr, (2003) Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 278, 50466-50473.
8. Klinge L, Laval S, Keers S, Haldane F, Straub V, Barresi R, &, Bushby K, (2007) From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J 21, 1768-1776.
9. Therrien C, Dodig D, Karpati G, &, Sinnreich M, (2006) Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions. J Neurol Sci 250, 71-78.
10. Davis DB, Doherty KR, Delmonte AJ, &, McNally EM, (2002) Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem 277, 22883-22888.
11. Segawa K, Suzuki J, &, Nagata S, (2011) Constitutive exposure of phosphatidylserine on viable cells. Proc Natl Acad Sci USA 108, 19246-19251.
12. Therrien C, Di Fulvio S, Pickles S, &, Sinnreich M, (2009) Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 48, 2377-2384.
13. Han WQ, Xia M, Xu M, Boini KM, Ritter JK, Li NJ, &, Li PL, (2012) Lysosome fusion to the cell membrane is mediated by the dysferlin C2A domain in coronary arterial endothelial cells. J Cell Sci 125, 1225-1234.
14. Xu L, Pallikkuth S, Hou Z, Mignery GA, Robia SL, &, Han R, (2011) Dysferlin forms a dimer mediated by the C2 domains and the transmembrane domain in vitro and in living cells. PLoS One 6, e27884.
15. Azakir BA, Di Fulvio S, Salomon S, Brockhoff M, Therrien C, &, Sinnreich M, (2012) Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. J Biol Chem 287, 27629-27636.
16. McNeil AK, Rescher U, Gerke V, &, McNeil PL, (2006) Requirement for annexin A1 in plasma membrane repair. J Biol Chem 281, 35202-35207.
17. 2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6, 449-461.
18. Bouter A, Gounou C, Berat R, Tan S, Gallois B, Granier T, d'Estaintot BL, Poschl E, Brachvogel B, &, Brisson AR, (2011) Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nat Commun 2, 270.
19. 2+ sensitivities. J Biol Chem 286, 17982-17991.
20. Roostalu U, &, Strahle U, (2012) In vivo imaging of molecular interactions at damaged sarcolemma. Dev Cell 22, 515-529.
21. Han R, &, Campbell KP, (2007) Dysferlin and muscle membrane repair. Curr Opin Cell Biol 19, 409-416.
22. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, et al,. (2009) MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 11, 56-64.
23. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, Song R, Hwang M, Jin L, Guo J, et al,. (2010) MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121, 2565-2574.
24. Wang X, Xie W, Zhang Y, Lin P, Han L, Han P, Wang Y, Chen Z, Ji G, Zheng M, et al,. (2010) Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res 107, 76-83.
25. Han R, (2011) Muscle membrane repair and inflammatory attack in dysferlinopathy. Skelet Muscle 1, 10.
26. Matsuda C, Miyake K, Kameyama K, Keduka E, Takeshima H, Imamura T, Araki N, Nishino I, &, Hayashi Y, (2012) The C2A domain in dysferlin is important for association with MG53 (TRIM72). PLoS Curr 4, e5035add8caff4.
27. Cacciottolo M, Belcastro V, Laval S, Bushby K, di Bernardo D, &, Nigro V, (2011) Reverse engineering gene network identifies new dysferlin-interacting proteins. J Biol Chem 286, 5404-5413.
28. Zhu H, Lin P, De G, Choi KH, Takeshima H, Weisleder N, &, Ma J, (2011) Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J Biol Chem 286, 12820-12824.
29. Hai A, &, Spira ME, (2012) On-chip electroporation, membrane repair dynamics and transient in-cell recordings by arrays of gold mushroom-shaped microelectrodes. Lab Chip 12, 2865-2873.
30. Evesson FJ, Peat RA, Lek A, Brilot F, Lo HP, Dale RC, Parton RG, North KN, &, Cooper ST, (2010) Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-4-associated pathway. J Biol Chem 285, 28529-28539.
31. Hernandez-Deviez DJ, Howes MT, Laval SH, Bushby K, Hancock JF, &, Parton RG, (2008) Caveolin regulates endocytosis of the muscle repair protein, dysferlin. J Biol Chem 283, 6476-6488.
32. Togo T, (2006) Disruption of the plasma membrane stimulates rearrangement of microtubules and lipid traffic toward the wound site. J Cell Sci 119, 2780-2786.
33. Matsuda C, Kameyama K, Tagawa K, Ogawa M, Suzuki A, Yamaji S, Okamoto H, Nishino I, &, Hayashi YK, (2005) Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol 64, 334-340.
34. de Morree A, Hensbergen PJ, van Haagen HH, Dragan I, Deelder AM, t Hoen PA, Frants RR, &, van der Maarel SM, (2010) Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 5, e13854.
35. Matsuda C, Kameyama K, Suzuki A, Mishima W, Yamaji S, Okamoto H, Nishino I, &, Hayashi YK, (2008) Affixin activates Rac1 via betaPIX in C2C12 myoblast. FEBS Lett 582, 1189-1196.
36. Huang Y, Laval SH, van Remoortere A, Baudier J, Benaud C, Anderson LV, Straub V, Deelder A, Frants RR, den Dunnen JT, et al,. (2007) AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 21, 732-742.
37. Azakir BA, Di Fulvio S, Therrien C, &, Sinnreich M, (2010) Dysferlin interacts with tubulin and microtubules in mouse skeletal muscle. PLoS One 5, e10122.
38. Di Fulvio S, Azakir BA, Therrien C, &, Sinnreich M, (2011) Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One 6, e28563.
39. Marg A, Schoewel V, Timmel T, Schulze A, Shah C, Daumke O, &, Spuler S, (2012) Sarcolemmal repair is a slow process and includes EHD2. Traffic 13, 1286-1294.
40. Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P, Baiget M, Matsuda C, &, Brown RH, (2001) Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 49, 130-134.
41. Krahn M, Beroud C, Labelle V, Nguyen K, Bernard R, Bassez G, Figarella-Branger D, Fernandez C, Bouvenot J, Richard I, et al,. (2009) Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 30, E345-375.
42. Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D, Pouget J, el Hammouda H, Beroud C, Urtizberea A, et al,. (2005) Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat 26, 165.
43. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, et al,. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20, 31-36.
44. Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, Richard I, Marchand S, Bourg N, Argov Z, et al,. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 20, 37-42.
45. Klinge L, Aboumousa A, Eagle M, Hudson J, Sarkozy A, Vita G, Charlton R, Roberts M, Straub V, Barresi R, et al,. (2010) New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 81, 946-953.
46. Cagliani R, Magri F, Toscano A, Merlini L, Fortunato F, Lamperti C, Rodolico C, Prelle A, Sironi M, Aguennouz M, et al,. (2005) Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat 26, 283.
47. Klinge L, Harris J, Sewry C, Charlton R, Anderson L, Laval S, Chiu YH, Hornsey M, Straub V, Barresi R, et al,. (2010) Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 41, 166-173.
48. Selcen D, Stilling G, &, Engel AG, (2001) The earliest pathologic alterations in dysferlinopathy. Neurology 56, 1472-1481.
49. Barthelemy F, Wein N, Krahn M, Levy N, &, Bartoli M, (2011) Translational research and therapeutic perspectives in dysferlinopathies. Mol Med 17, 875-882.
50. Blandin G, Beroud C, Labelle V, Nguyen K, Wein N, Hamroun D, Williams B, Monnier N, Rufibach LE, Urtizberea JA, et al,. (2012) UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene. Hum Mutat 33, E2317-2331.
51. Azakir BA, Di Fulvio S, Kinter J, &, Sinnreich M, (2012) Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. J Biol Chem 287, 10344-10354.
52. Schoewel V, Marg A, Kunz S, Overkamp T, Siegert Carrazedo R, Zacharias U, Daniel PT, &, Spuler S, (2012) Dysferlin-peptides reallocate mutated dysferlin thereby restoring function. PLoS One 7, e49603.
53. Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, Hayashi YK, &, Momoi T, (2007) Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet 16, 618-629.
54. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, Morandi L, Mora M, Cornelio F, &, Mantegazza R, (2003) Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 142, 130-136.
55. Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown RH Jr, &, Illa I, (2001) Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57, 2136-2138.
56. Nemoto H, Konno S, Nakazora H, Miura H, &, Kurihara T, (2007) Histological and immunohistological changes of the skeletal muscles in older SJL/J mice. Eur Neurol 57, 19-25.
57. Farini A, Sitzia C, Navarro C, D'Antona G, Belicchi M, Parolini D, Del Fraro G, Razini P, Bottinelli R, Meregalli M, et al,. (2012) Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exp Cell Res 318, 1160-1174.
58. Wenzel K, Zabojszcza J, Carl M, Taubert S, Lass A, Harris CL, Ho M, Schulz H, Hummel O, Hubner N, et al,. (2005) Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 175, 6219-6225.
59. Han R, Frett EM, Levy JR, Rader EP, Lueck JD, Bansal D, Moore SA, Ng R, Beltran-Valero de Bernabe D, Faulkner JA, et al,. (2010) Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 120, 4366-4374.
60. Moskovich O, &, Fishelson Z, (2007) Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem 282, 29977-29986.
61. Ricklin D, Hajishengallis G, Yang K, &, Lambris JD, (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11, 785-797.
62. Basu S, Binder RJ, Suto R, Anderson KM, &, Srivastava PK, (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12, 1539-1546.
63. Mellgren RL, (2010) A plasma membrane wound proteome: reversible externalization of intracellular proteins following reparable mechanical damage. J Biol Chem 285, 36597-36607.
64. Shi Y, Evans JE, &, Rock KL, (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521.
65. Scaffidi P, Misteli T, &, Bianchi ME, (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
66. Covian-Nares JF, Koushik SV, Puhl HL III, &, Vogel SS, (2010) Membrane wounding triggers ATP release and dysferlin-mediated intercellular calcium signaling. J Cell Sci 123, 1884-1893.
67. Kawai T, &, Akira S, (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11, 373-384.
68. Schreiner B, Voss J, Wischhusen J, Dombrowski Y, Steinle A, Lochmuller H, Dalakas M, Melms A, &, Wiendl H, (2006) Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J 20, 118-120.
69. Frost RA, Nystrom GJ, &, Lang CH, (2006) Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am J Physiol Regul Integr Comp Physiol 290, R773-784.
70. Boyd JH, Mathur S, Wang Y, Bateman RM, &, Walley KR, (2006) Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72, 384-393.
71. Cappelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, Coccia EM, Confalonieri P, Morandi L, Mora M, et al,. (2011) Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 76, 2079-2088.
72. Tournadre A, Lenief V, &, Miossec P, (2010) Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 62, 2144-2151.
73. Brunn A, Zornbach K, Hans VH, Haupt WF, &, Deckert M, (2012) Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 71, 855-867.
74. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, &, Hoffman EP, (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65, 826-834.
75. Jeudy S, Wardrop KE, Alessi A, &, Dominov JA, (2011) Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy. PLoS One 6, e22369.
76. Rawat R, Cohen TV, Ampong B, Francia D, Henriques-Pons A, Hoffman EP, &, Nagaraju K, (2010) Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 176, 2891-2900.
77. Bryant C, &, Fitzgerald KA, (2009) Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 19, 455-464.
78. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, &, Golenbock DT, (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9, 857-865.
79. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, &, Dixit VM, (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232.
80. Zhou R, Tardivel A, Thorens B, Choi I, &, Tschopp J, (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11, 136-140.
81. Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, Grant EP, Coyle AJ, Misaghi A, Hoffman HM, et al,. (2009) NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284, 12762-12771.
82. Martinon F, Petrilli V, Mayor A, Tardivel A, &, Tschopp J, (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241.
83. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, &, Tschopp J, (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14, 1583-1589.
84. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, et al,. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361.
85. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, &, Abbate A, (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 108, 19725-19730.
86. Zacharias U, Purfurst B, Schowel V, Morano I, Spuler S, &, Haase H, (2011) Ahnak1 abnormally localizes in muscular dystrophies and contributes to muscle vesicle release. J Muscle Res Cell Motil 32, 271-280.
87. Zhong Z, Zhai Y, Liang S, Mori Y, Han R, Sutterwala FS, &, Qiao L, (2013) TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun 4, 1611.
88. De Luna N, Gallardo E, Sonnet C, Chazaud B, Dominguez-Perles R, Suarez-Calvet X, Gherardi RK, &, Illa I, (2010) Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy. J Neuropathol Exp Neurol 69, 643-653.
89. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, et al,. (2011) Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123, 594-604.
90. Hoffman EP, Rao D, &, Pachman LM, (2002) Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheum Dis Clin North Am 28, 743-757.
91. Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, Kress W, Muller-Reible C, Vorgerd M, Urban P, et al,. (2013) Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 8, 26.
92. Cohen TV, Cohen JE, &, Partridge TA, (2012) Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response. Neuromuscul Disord 22, 648-658.
93. Chrousos GA, Kattah JC, Beck RW, &, Cleary PA, (1993) Side effects of glucocorticoid treatment. Experience of the optic neuritis treatment trial. JAMA 269, 2110-2112.
94. Baudy AR, Reeves EK, Damsker JM, Heier C, Garvin LM, Dillingham BC, McCall J, Rayavarapu S, Wang Z, Vandermeulen JH, et al,. (2012) Delta-9,11 modification of glucocorticoids dissociates nuclear factor-kappaB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exper Therapeut 343, 225-232.
95. Lerario A, Cogiamanian F, Marchesi C, Belicchi M, Bresolin N, Porretti L, &, Torrente Y, (2010) Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskelet Disord 11, 157.
96. Angelini C, Peterle E, Gaiani A, Bortolussi L, &, Borsato C, (2011) Dysferlinopathy course and sportive activity: clues for possible treatment. Acta Myol 30, 127-132.
97. Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, &, Pines M, (2013) Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol Histopathol 28, 211-226.
98. Millay DP, Maillet M, Roche JA, Sargent MA, McNally EM, Bloch RJ, &, Molkentin JD, (2009) Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 175, 1817-1823.
99. Lostal W, Bartoli M, Roudaut C, Bourg N, Krahn M, Pryadkina M, Borel P, Suel L, Roche JA, Stockholm D, et al,. (2012) Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One 7, e38036.
100. Krahn M, Wein N, Bartoli M, Lostal W, Courrier S, Bourg-Alibert N, Nguyen K, Vial C, Streichenberger N, Labelle V, et al,. (2010) A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2, 50ra69.
101. Nagaraju K, Rawat R, Veszelovszky E, Thapliyal R, Kesari A, Sparks S, Raben N, Plotz P, &, Hoffman EP, (2008) Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 172, 774-785.
102. Zhao P, Xu L, Ait-Mou Y, de Tombe PP, &, Han R, (2011) Equal force recovery in dysferlin-deficient and wild-type muscles following saponin exposure. J Biomed Biotechnol 2011, 235216.
103. Bischofberger M, Gonzalez MR, &, van der Goot FG, (2009) Membrane injury by pore-forming proteins. Curr Opin Cell Biol 21, 589-595.
104. Paidassi H, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehiwet B, Gaboriaud C, Arlaud GJ, &, Frachet P, (2008) C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 180, 2329-2338.
105. Martin M, Leffler J, &, Blom AM, (2012) Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem 287, 33733-33744.
106. Terrill JR, Radley-Crabb HG, Iwasaki T, Lemckert FA, Arthur PG, &, Grounds MD, (2013) Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies. FEBS J, doi: 10.1111/febs.12142
107. Nakagawa H, &, Komorita N, (1993) Complement component C3-derived neutrophil chemotactic factors purified from exudate of rat carrageenin-induced inflammation. Biochem Biophys Res Commun 194, 1181-1187.
108. Doherty DE, Downey GP, Worthen GS, Haslett C, &, Henson PM, (1988) Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils. Lab Invest 59, 200-213.
109. Fujita T, Hemmi S, Kajiwara M, Yabuki M, Fuke Y, Satomura A, &, Soma M, (2013) Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev 29, 220-226.